The Butantan Institute reported last week that it obtained promising results in preliminary tests of the single vaccine against influenza and covid-19. According to the São Paulo agency, tests in animal models showed production of antibodies induced by the immunizer against the three strains of influenza (H1N1, H3N2 and B) and against the new coronavirus.
+ Omicron or Influenza? See which virus is the deadliest
Butantan believes that clinical trials in humans can be started within a year. This step is crucial to verify the safety and effectiveness of the product.
According to the institute, the project for a new vaccine, conducted by Brazilian scientists in partnership with international bodies, has the potential to make it cheaper and increase the production capacity of vaccines for Brazil and other developing countries.
The American laboratory Novavax is also looking for a unique immunizer. Human trials began in September in Australia, after promising results from pre-clinical trials, according to the drugmaker. The expectation is to release data from the new testing phase this semester. Moderna, also an American company, is another one that has already announced plans to launch a single vaccine in 2023.
+ Omicron: Unexpected symptom of infection in children worries medical teams
+ Mercadão de SP vendors threaten customers with fruit scam
+ Video: Mother is attacked on social media for wearing tight clothes to take her son to school
+ Horoscope: check today’s forecast for your sign
+ What is known about fluorone?
+ Trick to squeeze lemons becomes a craze on social media
+ ‘Monster Ichthyosaur’ is discovered in Colombia
+ One twin became vegan, the other ate meat. Check the result
+ See which were the most stolen cars in SP in 2021
+ Expedition identifies giant squid responsible for ship sinking in 2011
+ US Agency warns: never wash raw chicken meat
#Single #flu #covid #vaccine #test #promising #result
Leave a Reply